Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
35 hedge funds and large institutions have $32.7M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 0 closing their positions.
178% more capital invested
Capital invested by funds: $11.8M → $32.7M (+$20.9M)
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
35% more funds holding
Funds holding: 26 → 35 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$1.49M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.23M |
| 3 |
Two Sigma Investments
New York
|
+$912K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$668K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$536K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$62.8K |
| 2 |
JP Morgan Chase
New York
|
-$19.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13.5K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$7.15K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$6.26K |
OPNT Hedge Fund Activity: Q3 2021 in Review
35 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q3 2021, worth a combined $32.7M — up 178% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OPNT positions and 0 closed out — a net gain of 9 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $1.49M. The largest seller was Wells Fargo, cutting an estimated $62.8K.
- 35 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q3 2021, up from 26 in Q2 2021.
- Funds reported $32.7M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q3 2021, up 178% quarter-over-quarter.
- 9 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 0 closed out, a net change of +9 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Two Sigma Advisers, an estimated $1.49M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Wells Fargo, an estimated $62.8K sold.
Based on aggregated 13F filings for Q3 2021.